Physician profile
Jayme Storms
NPI 1083078547
$4,638.11
in general payments reported to CMS, 2019-2025
25 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $735 · 2023: $996 · 2024: $1,320 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,343 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.33 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $790.03 | 2021-2025 | |
| Abbvie INC. | $643.26 | 2021-2025 | |
| Incyte Corporation | $619.08 | 2021-2025 | Opzelura |
| Amgen INC. | $409.54 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $313.60 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $312.76 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $212.04 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $210.25 | 2021-2024 | Ilumya |
| Janssen Biotech, INC. | $197.24 | 2021-2024 | Tremfya |
| Dermavant Sciences, INC. | $148.16 | 2023-2024 | Vtama |
| Ucb, INC. | $142.93 | 2021-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2023 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.75 | 2021 | |
| Pfizer INC. | $77.13 | 2021-2023 | |
| Galderma Laboratories, L.P. | $67.74 | 2022-2025 | Aklief, Nemluvio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $66.31 | 2025 | Vtama |
| Lilly USA, LLC | $38.27 | 2021-2022 | |
| Leo Pharma INC. | $29.46 | 2025 | Adbry |
| Smith+Nephew, INC. | $28.62 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.96 | 2023 | Spevigo |
| Sanofi-Aventis U.S. LLC | $21.55 | 2021 | |
| Biofrontera INC. | $20.19 | 2021 | |
| Kyowa Kirin, INC. | $19.56 | 2021 | |
| Strata Skin Sciences, INC. | $15.01 | 2024 | Xtrac |
| Verrica Pharmaceuticals INC. | $14.67 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayme Storms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.